European Psychiatry - Volume 41 - April 2017

271 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302 S267
nitive domains, and in psychosocial functioning as assessed by
either rating scales (SLOF and PSP) and performance-based mea-
sures (UPSA) at the 4-month time-point.
Conclusions CR improved psychosocial functioning in both group
of patients, however, they were more pronounced in TRS patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0472
Estradiol production suppressed by
prolactin in at-risk mental state and
first episode psychosis female
patients? Preliminary results
S. Ittig∗, E. Studerus , U. Heitz , S. Menghini-Müller , L. Egloff ,
K. Beck , L. Leanza , C. Andreou , A. Riecher-Rössler
University of Basel Psychiatric Hospital, Center for Gender Research
and Early Detection, Basel, Switzerland
∗ Corresponding author.
Introduction Clinical, epidemiological and basic research stud-
ies have confirmed that estradiol can have protective effects in
schizophrenic psychoses. At the same time many patients with
schizophrenic psychoses – even antipsychotic naïve at-risk men-
tal state (ARMS) patients show hyperprolactinemia and gonadal
dysfunction with estrogen deficiency in women and possibly
testosterone deficiency in men.
Aim To investigate the relation between the stress hormone pro-
lactin and the sex hormones estradiol in women and testosterone
in men in emerging psychosis.
Methods Forty-seven antipsychotic-naïve ARMS (38 men and
9 women) and 17 antipsychotic-naive first episode psychosis
(FEP) (14 men and 3 women) patients were recruited via the
Basel Früherkennung von Psychosen (FePsy) study. Blood was
taken under standardized conditions between 8 and 10 am after
an overnight fast and 30minutes of rest. We performed a linear
regression model to evaluate the association between prolactin
and sex hormones including age and current antidepressant use
as covariates.
Results In women, estradiol was negatively associated with
prolactin (ˇ = −1.28, P = 0.01) whereas in men there was a
positive association of testosterone with prolactin (ˇ = 0.52,
P = 0.031).
Conclusion The often observed estrogen deficiency in women
with psychosis could therefore be explained by the stress hor-
mone prolactin suppressing the gonadal axis already in very early
untreated stages of the emerging disease.
In ARMS or FEP men prolactin does not seem to influence the
gonadal axis in the same way as in women.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0473
Association between prolactin gene
polymorphism (–1149 G/T) and
hyperprolactinemia in anti-psychotic
treated patients with schizophrenia
S. Ivanova ∗ Osmanova Boiko ozhidaev
O. Fedorenko , E. Kornetova , A. Semke , N. Bokhan ,
B. Wilffert , A. Loonen
1 Mental Health Research Institute, Tomsk National Research Medical
Center of RAS, Molecular Genetics and Biochemistry Laboratory,
Tomsk, Russia
2 Mental Health Research Institute, Tomsk National Research Medical
Center of RAS, Department of Clinical Psychiatry, Tomsk, Russia
3 University of Groningen, Department of Pharmacy, Groningen, The
Netherlands
∗ Corresponding author.
Hyperprolactinemia (HPRL) is a classical side effect of anti-
psychotic drugs. Extrapituitary prolactin (PRL) production is
regulated by an alternative promoter, which contains the func-
tional single nucleotide polymorphism – 1149 G/T (rs134,1239) in
prolactin gene. We examined whether this polymorphism is asso-
ciated with hyperprolactinemia in patients with schizophrenia.
The experimental group comprised 443 patients with schizophre-
nia. The control group comprised 126 healthy persons. The
PRL concentration was measured in serum using the AccuBind
ELISA Microwells kit. The functional polymorphism – 1149 G/T
(rs134,1239) of the PRL gene was genotyped using the The
MassARRAY® system. Genotype and allele frequencies were com-
pared using 2 test. A total of 227 patients suffered from HPRL
(98 males/129 females) according to the criteria of hyperpro-
lactinemia. The frequency of genotypes and alleles in patients
with schizophrenia did not differ from those in control subjects. A
comparison between patients with schizophrenia with and with-
out hyperprolactinemia revealed that the frequency of G allele
in patients with hyperprolactinemia is significantly higher than
in patients without hyperprolactinemia ( 2 = 7.25; P = 0.007; OR =
1.44 [1.10–1.89]). Accordingly, the genotype GG was found to be
more often in patients with hyperprolactinemia than without it
( 2 = 9.49; P = 0.009). A significant association of the polymorphic
variant rs134,1239 with the development of hyperprolactinemia in
patients with schizophrenia treated with anti-psychotic drugs was
revealed. Therefore, the serum concentration of prolactin in anti-
psychotic treatment patients with schizophrenia may also give an
indication of the activity of gene regulating extrapituitary prolactin
expression.
The study was supported by the Russian Science Foundation, Grant
14-35-00023.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0474
Changing the obesogenic
environment to improve
cardiometabolic health in residential
patients with a severe mental Illness:
ELIPS, a randomized controlled trial
F. Jörg ∗, A. Looijmans , A. Stiekema , L. Van der Meer ,
R. Schoevers , E. Corpeleijn
1 University Medical Center Groningen UMCG, ICPE, Groningen, The
Netherlands
2 University Medical Center Groningen UMCG, Epidemiology,
Groningen, The Netherlands
3 Lentis, Lentis Research, Groningen, The Netherlands
4 University Medical Center Groningen UMCG, UCP, Groningen, The
Netherlands
∗ Corresponding author.
Introduction The life expectancy of severe mentally ill (SMI)
patients is shortened up to 30 years, due to cardiometabolic dis-
eases, partly caused by unhealthy lifestyles behaviors. In residential
facilities, adopting a healthy lifestyle is hampered by the obeso-
genic environment; an obesity promoting environment.
Objective To determine, the effectiveness of a 12month lifestyle
intervention addressing the obesogenic environment to improve
cardiometabolic health of SMI residential patients.
Methods The effectiveness of lifestyle interventions in psychi-
atry (ELIPS) trial is a multi-site, cluster randomized controlled
pragmatic trial. Twenty-nine sheltered and long-term clinical care
teams serving SMI patients in the Netherlands were randomized